Increased deaths shadow AstraZeneca, Daiichi's Enhertu first-line lung cancer data

A phase 3 trial shows AstraZeneca and Daiichi Sankyo's Enhertu increased progression-free survival in HER2-mutant non-small cell lung cancer but revealed a 15% higher risk of death compared to standard treatment, complicating potential FDA approval.

This Wire brief sits within Fusion42's coverage of Biotech.